Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

• Status: Completed
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a Phase 1, dose-escalation study in female patients with recurrent or persistent gynecologic tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vector Oncology
• Collaborator: GlaxoSmithKline
• Treatments: Topotecan

Criteria

Inclusion Criteria:

• Subjects must provide written informed consent prior to the performance of study specific procedures, and must be willing to comply with treatment and follow-up.

• Female patients, greater than 18 years of age with a histologically confirmed recurrent/persistent gynecologic malignancy.

• For patients with recurrent/persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: persistent disease = progression during primary platinum therapy; recurrent disease = disease that recurs ≤ 12 months after discontinuing primary platinum therapy; if disease recurrence occurs > 12 months after discontinuing primary platinum therapy, there must be progression either during a 2nd platinum therapy or < 6 months after discontinuing the 2nd platinum therapy.

• For patients with other gynecologic malignancies:

• Malignancy is metastatic or unresectable and no curative or palliative measures exist or are no longer effective.

• Maximum of two total prior treatments (this includes neoadjuvant, adjuvant, and metastatic settings) for the recurrent or persistent gynecologic tumors including chemotherapy, hormonal therapy, investigational therapy, radiation therapy, etc.)

• Disease may be measurable or non-measurable according to RECIST version 1.0

• Gynecologic Oncology Group (GOG) performance status of 0,1,or 2

• Must have a life expectancy of at least six months

• Adequate bone marrow, liver, renal, and cardiac function at study entry as assessed by the following:

• Hemoglobin > 9.0 g/dL.

• Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L.

• Platelet count ≥ 100 x 10^9/L.

• Prothrombin time (PT) or international normalized ratio (INR) < 1.2 x upper limit of normal (ULN).

• Partial thromboplastin time (PTT) < 1.2 x ULN.

• Total bilirubin ≤ 1.5 x ULN.

• Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN.

• Creatinine ≤ 1.5 mg/dL or if serum creatinine is greater than 1.5 mg/dL, calculated creatinine clearance must be > 50 mL/min

• Urine dipstick for protein < 2+ or urine protein creatinine (UPC) ratio < 1.0.

• Left ventricular ejection fraction (LVEF) ≥ 50% or the institutional lower limit of normal (LLN)

• Patients must be physiologically incapable of becoming pregnant, be postmenopausal, or have a negative pregnancy test and agree to use adequate contraception.

Exclusion Criteria:

• Treatment naive patients.

• Repetitive or prolonged neutropenia or thrombocytopenia during previous therapy.

• Concurrent malignancy other than malignancies under study. Subjects who have had another malignancy and have been disease free for 3 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.

• Prior radiation therapy.

• Myelosuppressive chemotherapy within the past 28 days or has not recovered from the myelosuppressive effects of recent chemotherapy.

• Use of an investigational agent, including an investigational anti-cancer agent, immunotherapy, biological therapy, or hormonal therapy within 28 days prior to the first dose of study treatment.

• Prior major surgery or trauma within 28 days prior to the first dose of study treatment and/or presence of any non-healing wound, fracture, or ulcer.

• History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis.

• Inability to swallow a capsule or clinically significant gastrointestinal abnormalities including, but not limited to:

• Malabsorption syndrome

• Major resection of the stomach or small bowel that could affect the absorption of study treatment

• Active peptic ulcer disease

• Inflammatory bowel disease

• Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation

• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment.

• Unresolved bowel obstruction or diarrhea ≥ Grade 1

• Known intraluminal metastatic lesion(s) with risk of bleeding

• Known endobronchial lesions or involvement of large pulmonary vessels by tumor.

• Presence of uncontrolled infection.

• Prolongation of corrected QT interval > 480 milliseconds.

• History of any one or more of the following cardiovascular conditions within the past 6 months:

• Cardiac angioplasty or stenting

• Myocardial infarction

• Unstable angina

• Coronary artery bypass graft

• Symptomatic peripheral vascular disease

• Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)

• Poorly controlled hypertension (defined as systolic blood pressure of > 140 mmHg or diastolic blood pressure of > 90 mmHg). Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry.

• History of cerebrovascular accident, transient ischemic attack, pulmonary embolism, or insufficiently treated deep vein thrombosis (DVT) within the past 6 months. Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible

• Evidence of active bleeding or bleeding diathesis.

• Recent hemoptysis in excess of 2.5 mL within 8 weeks of 1st dose of study treatment.

• Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.

• Use of any prohibited medication within 14 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study treatment and during the study.

• Prior use of any investigational or licensed anti-angiogenic agent, including topotecan, bevacizumab, thalidomide, and agents that target vascular endothelial growth factor (VEGF), VEGF receptors, or platelet-derived growth factor (PDGF).

• Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.

• Known hypersensitivity to topoisomerase I inhibitors or pazopanib.

• Administration of any non-oncologic investigational drug within 30 days or five half-lives of a drug (whichever is longer) prior to the first dose of study treatment.